Biomerica (BMRA) Competitors $3.35 -0.16 (-4.56%) Closing price 05/22/2025 03:58 PM EasternExtended Trading$3.27 -0.08 (-2.39%) As of 05:49 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock BMRA vs. ITRM, TNYA, NRXP, ELYM, RANI, ALGS, SPRO, LVTX, AKTX, and COEPShould you be buying Biomerica stock or one of its competitors? The main competitors of Biomerica include Iterum Therapeutics (ITRM), Tenaya Therapeutics (TNYA), NRx Pharmaceuticals (NRXP), Eliem Therapeutics (ELYM), Rani Therapeutics (RANI), Aligos Therapeutics (ALGS), Spero Therapeutics (SPRO), LAVA Therapeutics (LVTX), Akari Therapeutics (AKTX), and Coeptis Therapeutics (COEP). These companies are all part of the "pharmaceutical products" industry. Biomerica vs. Iterum Therapeutics Tenaya Therapeutics NRx Pharmaceuticals Eliem Therapeutics Rani Therapeutics Aligos Therapeutics Spero Therapeutics LAVA Therapeutics Akari Therapeutics Coeptis Therapeutics Biomerica (NASDAQ:BMRA) and Iterum Therapeutics (NASDAQ:ITRM) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, media sentiment, risk, earnings, analyst recommendations, dividends, community ranking, institutional ownership and profitability. Do analysts recommend BMRA or ITRM? Iterum Therapeutics has a consensus price target of $9.00, indicating a potential upside of 866.60%. Given Iterum Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Iterum Therapeutics is more favorable than Biomerica.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biomerica 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Iterum Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Do insiders and institutionals have more ownership in BMRA or ITRM? 22.3% of Biomerica shares are held by institutional investors. Comparatively, 9.2% of Iterum Therapeutics shares are held by institutional investors. 15.0% of Biomerica shares are held by company insiders. Comparatively, 9.2% of Iterum Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has more risk & volatility, BMRA or ITRM? Biomerica has a beta of 0.37, meaning that its share price is 63% less volatile than the S&P 500. Comparatively, Iterum Therapeutics has a beta of 2.91, meaning that its share price is 191% more volatile than the S&P 500. Which has better earnings & valuation, BMRA or ITRM? Biomerica has higher revenue and earnings than Iterum Therapeutics. Biomerica is trading at a lower price-to-earnings ratio than Iterum Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBiomerica$5.68M1.50-$5.98M-$2.32-1.44Iterum TherapeuticsN/AN/A-$24.77M-$0.99-0.94 Does the MarketBeat Community believe in BMRA or ITRM? Iterum Therapeutics received 5 more outperform votes than Biomerica when rated by MarketBeat users. However, 67.82% of users gave Biomerica an outperform vote while only 63.11% of users gave Iterum Therapeutics an outperform vote. CompanyUnderperformOutperformBiomericaOutperform Votes13767.82% Underperform Votes6532.18% Iterum TherapeuticsOutperform Votes14263.11% Underperform Votes8336.89% Is BMRA or ITRM more profitable? Iterum Therapeutics has a net margin of 0.00% compared to Biomerica's net margin of -100.52%. Iterum Therapeutics' return on equity of 0.00% beat Biomerica's return on equity.Company Net Margins Return on Equity Return on Assets Biomerica-100.52% -90.19% -64.54% Iterum Therapeutics N/A N/A -90.85% Does the media favor BMRA or ITRM? In the previous week, Biomerica and Biomerica both had 1 articles in the media. Biomerica's average media sentiment score of 0.00 equaled Iterum Therapeutics'average media sentiment score. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Biomerica 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Iterum Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral SummaryIterum Therapeutics beats Biomerica on 9 of the 15 factors compared between the two stocks. Get Biomerica News Delivered to You Automatically Sign up to receive the latest news and ratings for BMRA and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart BMRA vs. The Competition Export to ExcelMetricBiomericaDiagnostic substances IndustryMedical SectorNASDAQ ExchangeMarket Cap$8.53M$2.61B$5.33B$8.39BDividend YieldN/A0.73%5.21%4.11%P/E Ratio-9.857.4726.7919.70Price / Sales1.5035.77393.69121.79Price / CashN/A15.7538.2534.62Price / Book8.595.496.774.50Net Income-$5.98M-$65.73M$3.23B$248.22M7 Day Performance-7.97%-0.44%0.42%-0.80%1 Month Performance-8.47%0.30%9.06%11.52%1 Year Performance-34.88%-15.77%18.55%8.99% Biomerica Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)BMRABiomerica0.1444 of 5 stars$3.35-4.6%N/A-33.8%$8.53M$5.68M-9.8560News CoverageITRMIterum Therapeutics1.8386 of 5 stars$1.01-1.0%$9.00+791.1%-34.4%$36.04MN/A-0.7710TNYATenaya Therapeutics3.4303 of 5 stars$0.41-0.7%$6.25+1,420.3%-90.2%$36.01MN/A-0.29110NRXPNRx Pharmaceuticals1.9107 of 5 stars$2.08+2.0%$28.50+1,270.2%-31.0%$35.83MN/A-0.972Analyst UpgradeELYMEliem TherapeuticsN/A$1.19flatN/A-84.6%$35.41MN/A-2.259News CoverageRANIRani Therapeutics2.2543 of 5 stars$0.61-16.0%$12.00+1,857.6%-87.6%$35.24M$1.03M-0.58110News CoverageAnalyst RevisionALGSAligos Therapeutics3.4151 of 5 stars$5.68+26.8%$70.00+1,132.4%-65.6%$34.73M$3.27M-0.4390Gap UpSPROSpero Therapeutics4.1095 of 5 stars$0.61-1.6%$5.00+719.7%-53.6%$34.11M$27.40M8.72150Gap DownLVTXLAVA Therapeutics2.0254 of 5 stars$1.28+2.3%$3.17+147.6%-53.3%$33.64M$11.98M-1.2460Gap DownAKTXAkari TherapeuticsN/A$1.41+11.9%N/A-33.2%$33.51MN/A0.009News CoverageAnalyst ForecastCOEPCoeptis Therapeutics0.239 of 5 stars$9.90+4.2%N/A+70.4%$33.31MN/A-1.712Analyst UpgradeGap Up Related Companies and Tools Related Companies Iterum Therapeutics Alternatives Tenaya Therapeutics Alternatives NRx Pharmaceuticals Alternatives Eliem Therapeutics Alternatives Rani Therapeutics Alternatives Aligos Therapeutics Alternatives Spero Therapeutics Alternatives LAVA Therapeutics Alternatives Akari Therapeutics Alternatives Coeptis Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:BMRA) was last updated on 5/23/2025 by MarketBeat.com Staff From Our PartnersWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredElon Set to Shock the World on June 1st?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredGold Alert: The Truth About Fort Knox Is ComingOwning physical gold isn’t the best way to profit. I’ve found a better way to invest in gold—one that’s alr...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biomerica, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Biomerica With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy BMRA Stock Free BMRA Stock Alerts